Tellgen Corporation

300642

CNE100002P42

Medical Equipment, Supplies & Distribution

End-of-day quote Shenzhen S.E. Other stock markets 23:00:00 23/05/2024 BST			5-day change	1st Jan Change
12.99 ^CNY	-2.18%		-7.54%	-26.40%

05-06	Tranche Update on Tellgen Corporation's Equity Buyback Plan announced on February 6, 2024.	CI
05-05	Tellgen Corporation's Equity Buyback announced on February 6, 2024, has closed with 1,946,150 shares, representing 1.2% for CNY 25.98 million.	CI

Tellgen Corporation authorizes a Buyback Plan.

October 25, 2021

The Board of Directors of Tellgen Corporation has authorized a buyback plan on October 26, 2021.

Latest news about Tellgen Corporation

Tranche Update on Tellgen Corporation's Equity Buyback Plan announced on February 6, 2024.	05-06	CI
Tellgen Corporation's Equity Buyback announced on February 6, 2024, has closed with 1,946,150 shares, representing 1.2% for CNY 25.98 million.	05-04	CI
Tellgen Corporation Reports Earnings Results for the First Quarter Ended March 31, 2024	04-22	CI
Tranche Update on Tellgen Corporation's Equity Buyback Plan announced on February 6, 2024.	04-01	CI
Tellgen Corporation announces an Equity Buyback for CNY 50 million worth of its shares.	02-06	CI
Tellgen Corporation authorizes a Buyback Plan.	02-05	CI
Tellgen Corporation Announces Board Appointments	12-26	CI
Tellgen Corporation Reports Earnings Results for the Nine Months Ended September 30, 2023	24/10/23	CI
Tellgen Corporation, Shanghai Tellgen Diagnostic Technology Co., Ltd., Shanghai Maishi Jingwu Enterprise Management Partnership Enterprise (Limited Partnership), Yao Beier, Niu Zhengxiang and Zhan Hong agreed to acquire additional 5.71% stake in Shanghai Maishi Biotechnology Co., Ltd. from Wu Liang for CNY 1.4 million.	27/09/23	CI
Tellgen Corporation Reports Earnings Results for the Half Year Ended June 30, 2023	18/08/23	CI
Tellgen Corporation Approves Cash Dividend for 2022, Payable on 23 May 2023	15/05/23	CI
Tellgen Corporation Proposes Final Cash Dividend for 2022	24/04/23	CI
Tellgen Corporation Reports Earnings Results for the First Quarter Ended March 31, 2023	21/04/23	CI
Tellgen Corporation Reports Earnings Results for the Nine Months Ended September 30, 2022	28/10/22	CI
Tranche Update on Tellgen Corporation's Equity Buyback Plan announced on October 27, 2021.	26/10/22	CI
Tellgen Corporation's Equity Buyback announced on October 27, 2021, has expired with 1,062,840 shares, representing 0.65% for CNY 25.43 million.	24/10/22	CI
Tranche Update on Tellgen Corporation's Equity Buyback Plan announced on October 27, 2021.	10/10/22	CI
Tellgen Corporation Reports Earnings Results for the Half Year Ended June 30, 2022	19/08/22	CI
Tranche Update on Tellgen Corporation's Equity Buyback Plan announced on October 27, 2021.	03/07/22	CI
Tellgen Corporation Announces Final Distribution on A Shares for the Year 2021, Payable on 24 May 2022	17/05/22	CI
Tellgen Corporation Approves Cash Dividend for the Year 2021	16/05/22	CI
Tellgen Corporation Announces Profit Distribution Proposal for 2021	25/04/22	CI
Tellgen Corporation Reports Earnings Results for the First Quarter Ended March 31, 2022	22/04/22	CI
Tellgen Corporation Reports Earnings Results for the Full Year Ended December 31, 2021	22/04/22	CI
Tranche Update on Tellgen Corporation's Equity Buyback Plan announced on October 27, 2021.	01/04/22	CI

Tellgen Corp is a company engaged in research, development, production and sales of in vitro diagnostic reagents and instruments. The Company's products are comprised of immunodiagnostic products, molecular diagnostic products and biochemical diagnostic products, including tumor marker detection products, human papillomavirus (HPV) nucleic acid testing products, autoimmune disease detection products and lung cancer methylation mutation detection products.

Sector

Medical Equipment, Supplies & Distribution

Calendar

18/08/2024 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Quarterly earnings - Rate of surprise

Company calendar

Sector Diagnostic & Testing Substances

	1st Jan change	Capi.
TELLGEN CORPORATION	-26.40%	293M
BIOMÉRIEUX	-4.92%	12.27B
SHENZHEN NEW INDUSTRIES BIOMEDICAL ENGINEERING CO., LTD.	-5.82%	7.99B
DIASORIN S.P.A.	+5.43%	5.69B
LANTHEUS HOLDINGS, INC.	+26.16%	5.42B
AUTOBIO DIAGNOSTICS CO., LTD.	-9.58%	4.13B
10X GENOMICS, INC.	-59.63%	2.7B
ANDON HEALTH CO., LTD.	+8.44%	2.6B
VITROLIFE AB	-3.70%	2.38B
MYRIAD GENETICS, INC.	+21.00%	2.1B

Diagnostic & Testing Substances